Correction To Tetra Bio-Pharma News Release Dated February 25th

Rhea-AI Summary

Tetra Bio-Pharma (OTCQB: TBPMF) issued a correction regarding its February 25, 2021 news release. The reported estimate for peak sales by 2026 attributed to DanCann Pharma's CCO John Morell Frellsen was incorrectly stated as 55 million DKK. The accurate figure is 55 million USD. Tetra Bio-Pharma focuses on developing immunomodulator drugs and has a clinical program approved by both the FDA and Health Canada, aimed at addressing various medical conditions.

Positive

• Accurate sales forecast of $55M USD by 2026 enhances credibility.
• Tetra's focus on immunomodulator drug development positions it well in the biopharma sector.

Negative

• None.

OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP)(OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In the statement attributed to DanCann Pharma's CCO John Morell Frellsen, the estimate of peak sales by 2026 is cited at $55M DKK. In fact, the estimate of peak sales by 2026 is $55M USD.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas. For more information visit: www.dancann.com.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) is a biopharmaceutical pioneer in immunomodulator drug discovery and development with a FDA and a Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
investors@tetrabiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

View source version on accesswire.com:
https://www.accesswire.com/633951/Correction-To-Tetra-Bio-Pharma-News-Release-Dated-February-25th

FAQ

What is the corrected sales estimate for Tetra Bio-Pharma?

The corrected sales estimate for Tetra Bio-Pharma is $55 million USD by 2026.

What does Tetra Bio-Pharma focus on?

Tetra Bio-Pharma focuses on immunomodulator drug discovery and development.

What is the stock symbol for Tetra Bio-Pharma?

The stock symbol for Tetra Bio-Pharma is TBPMF.

When was Tetra Bio-Pharma's correction released?

Tetra Bio-Pharma's correction was released on March 8, 2021.